Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) saw a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 76,800 shares, a decrease of 20.7% from the September 30th total of 96,900 shares. Based on an average daily volume of 1,069,300 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

Separately, Bank of America upgraded shares of Bayer Aktiengesellschaft from an "underperform" rating to a "neutral" rating in a research report on Friday, September 6th. One equities research analyst has rated the stock with a sell rating and eight have issued a hold rating to the company. According to MarketBeat, Bayer Aktiengesellschaft has a consensus rating of "Hold".

Bayer Aktiengesellschaft Stock Up 1.4 %

Bayer Aktiengesellschaft stock traded up $0.10 on Monday, hitting $7.09. 481,053 shares of the stock traded hands, compared to its average volume of 1,336,149. The company has a current ratio of 1.27, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. The firm has a market cap of $27.86 billion, a P/E ratio of -8.15 and a beta of 1.08. The business's fifty day simple moving average is $7.69 and its 200 day simple moving average is $7.48. Bayer Aktiengesellschaft has a 1 year low of $6.82 and a 1 year high of $11.34.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.25 EPS for the quarter, meeting the consensus estimate of $0.25. Bayer Aktiengesellschaft had a positive return on equity of 16.96% and a negative net margin of 2.74%. The business had revenue of $12 billion during the quarter. As a group, sell-side analysts forecast that Bayer Aktiengesellschaft will post 1.38 earnings per share for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.